Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts by Larbouret, C. et al.
Annals of Oncology 21: 98–103, 2010
doi:10.1093/annonc/mdp496
Published online 4 November 2009
original article
Combined cetuximab and trastuzumab are superior to
gemcitabine in the treatment of human pancreatic
carcinoma xenografts
C. Larbouret1,2,3,4, B. Robert1,2,3,4, C. Bascoul-Mollevi4, F. Penault-Llorca5, A. Ho-Pun-Cheung4,
S. Morisseau1,2,3,4, I. Navarro-Teulon1,2,3,4, J.-P. Mach6, A. Pe`legrin1,2,3,4* & D. Azria1,2,3,4,7
1Institut de Recherche en Cance´rologie de Montpellier, Montpellier; 2Institut National de la Sante´ et de la Recherche Me´dicale, U896, Montpellier; 3Universite´
Montpellier1, Montpellier; 4CRLC Val d’Aurelle Paul Lamarque, Montpellier; 5Department of Pathology Centre Jean Perrin, Clermont-Ferrand; 6Institut de Biochimie,
Universite´ de Lausanne, Epalinges, Switzerland and 7Department of Radiotherapy CRLC Val d’Aurelle Paul Lamarque, Montpellier, France
Received 17 August 2009; accepted 8 September 2009
Background: Pancreatic carcinoma remains a treatment-refractory cancer with a poor prognosis. Here, we
compared anti-epidermal growth factor receptor (EGFR) and anti-HER2 monoclonal antibodies (2mAbs) injections with
standard gemcitabine treatment on human pancreatic carcinoma xenografts.
Materials and methods: Nude mice, bearing human pancreatic carcinoma xenografts, were treated with either
combined anti-EGFR (cetuximab) and anti-HER2 (trastuzumab) or gemcitabine, and tumor growth was observed.
Results and conclusion: In first-line therapy, mice survival was significantly longer in the 2mAbs group compared
with gemcitabine (P < 0.0001 for BxPC-3, P = 0.0679 for MiaPaCa-2 and P = 0.0019 for Capan-1) and with controls
(P < 0.0001). In second-line therapy, tumor regressions were observed after replacing gemcitabine by 2mAbs
treatment, resulting in significantly longer animal survival compared with mice receiving continuous gemcitabine
injections (P = 0.008 for BxPC-3, P = 0.05 for MiaPaCa-2 and P < 0.001 for Capan-1). Therapeutic benefit of 2mAbs
was observed despite K-Ras mutation. Interestingly, concerning the mechanism of action, coinjection of F(ab#)2
fragments from 2mAbs induced significant tumor growth inhibition, compared with controls (P = 0.001), indicating that
the 2mAbs had an Fc fragment-independent direct action on tumor cells. This preclinical study demonstrated
a significant improvement of survival and tumor regression in mice treated with anti-EGFR/anti-HER2 2mAbs in first-
and second-line treatments, compared with gemcitabine, independently of the K-Ras status.
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introduction
Pancreatic cancer is the fourth leading cause of cancer death in
both men and women. Currently, most pancreatic cancer
patients die within a year of diagnosis. When the tumor
becomes symptomatic, 60%–80% of the patients already
have locally advanced or metastatic disease, allowing
essentially palliative therapy, with a 5-year survival rate
of <5% [1].
Recent evaluation of gemcitabine-based combination
chemotherapy trials in advanced pancreatic cancer has
demonstrated significant, but low response rates and
disappointing effects on survival [2]. The strategies of earlier
attack on cancer by perioperative adjuvant or neo-adjuvant
therapy were expected to be more promising. However, the
recently reported retrospective and prospective analyses of
adjuvant chemoradiotherapy of pancreas carcinoma [3], as well
as the results of preoperative chemoradiation therapies [4],
have again demonstrated significant, but very modest
therapeutic gains. Similarly, the results from a recent phase III
trial, evaluating the advantage of the association of erlotinib
with gemcitabine, showed a significant, but low improvement,
as compared with gemcitabine-alone treatment, with a median
survival of 6.24 versus 5.91 months, as well as a 1-year survival
of 23% versus 17%, respectively [5].
In the field of mAb therapies and following the
demonstration of the expression of both epidermal growth
factor receptor (EGFR) and HER2 in pancreatic carcinomas
[6, 7] and the known implication of those receptors in the
malignant phenotype [8–11], we have recently demonstrated
that the coinjection of anti-EGFR and anti-HER2 mAbs had
a significant synergic effect in the treatment of human
pancreatic carcinoma xenografts, as compared with the effect of
each mAb alone [12]. Our results were recently confirmed and
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extended by the demonstration that different pairs of anti-
HER2 mAbs had a synergistic antitumor effect [13].
Here, we are evaluating, if the combined anti-EGFR/anti-
HER2 mAbs (2mAbs) targeted therapy can result in better
efficacy than the current standard chemotherapy, gemcitabine,
in a first- and second-line therapy.
methods
monoclonal antibodies and drugs
Cetuximab was purchased from Merck KGaA (Darmstadt, Germany),
trastuzumab from Roche Pharma AG (Grenzach-Wyhlen, Germany) and
gemcitabine from Lilly France (Pages, France). F(ab#)2 fragments of
cetuximab and trastuzumab were prepared by pepsine digestion followed by
filtration on a Superdex 200 column. Absence of intact mAb contamination
was checked by lack of any cytotoxicity induction by natural killer cells
on antigen-positive target cells [14].
cell lines
BxPC-3 and MiaPaCa-2 pancreatic cell lines were from ATCC (Rockville,
MD). The Capan-1 was provided by L. Buscail (Toulouse, France).
xenograft study and treatment procedure
All in vivo experiments were carried out in compliance with the national
regulations and ethical guidelines for experimental animal studies in an
accredited establishment (Agreement No. B34-172-27). Six-week-old
female athymic mice (Harlan, Le Malcourlet, France) were xenografted
subcutaneously with BxPC-3 (3.5 · 106), MiaPaCa-2 (5 · 106) and Capan-1
(10 ·106) cells. Tumor-bearing mice were randomized when tumors
reached a minimum of 50 mm3 and killed when tumor reached a volume
larger than 1000 mm3.
In first line, mice were treated twice a week either by intraperitoneal
injections of combined trastuzumab/cetuximab (ratio 1 : 1; 2 mg/kg of each
mAb) or gemcitabine (150 mg/kg) diluted in 0.15-ml saline.
In second line, 20 mice were treated twice a week with gemcitabine alone
(150 mg/kg). For 10 mice presenting a tumor progression (volume increase
at least two-fold from initial measurement) the gemcitabine treatment was
replaced by the combined trastuzumab/cetuximab intraperitoneal
injections twice a week (ratio 1 : 1; 2 mg/kg). The other 10 mice were
continuously treated by gemcitabine.
To determine the implication of the Fc fragment portion of antibodies,
BxPC-3 xenografted mice were treated twice a week for 4 weeks with
F(ab#)2 fragments from both trastuzumab and cetuximab (ratio 1 : 1; 1.35
mg/kg of each fragment) or cetuximab F(ab#)2 alone, at the same dose,
or intact trastuzumab and cetuximab (ratio 1 : 1; 2 mg/kg). The
concentration of fragments was adjusted to be at the same molarity (2 lM)
as the intact antibodies.
Tumor dimensions were measured with a caliper and the volumes
calculated by the formula: D1 · D2 · D3/2. In Figure 3, tumor growth is
expressed as the log of tumor progression: log [final volume (t)/initial
volume (t0)].
K-Ras mutation analysis
High-molecular weight DNA was extracted using a Qiamp DNA mini kit
(Qiagen, Courtaboeuf, France). Direct sequencing of the K-Ras gene codon
12 and 13 was done with a 3130 Genetic Analyzer (Applied Biosystems,
Courtaboeuf, France), using the Bigdye terminators v1.1 cycle sequencing
kit (Applied Biosystems).
immunohistochemical analyses
Seven days after treatment, tumors were harvested and fixed 12 h in
buffered formalin and embedded in paraffin.
Ki-67 (MiB1; Dako Corporation, Glustrup, Denmark), EGFR (3C6;
Ventana Medical Systems, llkirch, France) and pEGFR (tyr 1068, 1H12; Cell
Signalling Technology, Beverly, MA) immunostaining were carried out on
3-mm sections with a BenchmarkXT immunostainer (Ventana Medical
Systems). Sections were scored under light microscopy by two independent
pathologists, who analyzed five different fields per section. Error bars
correspond to results obtained in the different fields.
For EGFR the two plus or more intensity staining of tumor cells
membrane was scored positively, while for Ki-67 index and pEGFR the
percentage of tumor cells with one plus nuclear and/or cytoplasmic staining
was recorded positively. The results are expressed on histograms.
western blot analysis
Seven days after treatment, tumors were harvested and lysed as
described [12].
After electrophoresis, the proteins were transferred to a polyvinylidene
difluoride membranes (Millipore Co., Bedford, MA) which were saturated
in phosphate-buffered saline containing 0.1% Tween 20 and 5% nonfat
dry milk and then incubated with the antibodies against the phosphorylated
forms of AKT (Cell Signaling Technology). To ensure equal loading,
immunoblots were also probed with anti-glyceraldehyde-3-phosphate
dehydrogenase antibody (Chemicon International, Millipore SAS,
Molsheim, Australia).
statistical analyses
A linear mixed regression model was used to determine the relationship
between tumor growth and the number of days after implantation. The
fixed part of the model included variables corresponding to the number of
days after implantation and to different groups. Interaction terms were
built into the model. Random intercept and random slope were included to
take into account time effect. The coefficients of the model were estimated
by maximum likelihood and considered significant at the 0.05 level.
Survival rates were estimated from the date of the xenograft until the date
when the tumor reach a volume of 1000 mm3 using the Kaplan–Meier
method. Median survival was presented with 95% confidence intervals.
Survival curves were compared using the log-rank test. Statistical analysis
was carried out using STATA 10.0 software.
results
pancreatic cell lines characteristics
Immunohistochemical analyses of the three human pancreatic
carcinoma xenografted in nude mice showed a very low HER2
expression, but a high level of EGFR, classified as +++ for both
BxPC-3 and Capan-1 and as ++ for MiaPaCa-2 (Table 1). When
tested by flow cytometry [15], the three pancreatic carcinoma cell
lines showed a moderate expression of HER2 (Table 1).
Table 1. EGFR and HER2 expression and K-Ras status of the three
human pancreatic cell lines
Cell lines EGFR HER2 Sequencing
IHC FACScan
(MFI)
IHC FACScan
(MFI)
K-Ras
status
BxPC-3 3+ 156 ND 37.0 WT
MiaPaCa-2 2+ 31 ND 10.7 M
Capan-1 3+ 135 ND 10.4 M
EGFR, epidermal growth factor receptor; IHC, immunohistochemistry;
ND, nondetectable; MFI, mean fluorescence intensity; WT, wild type;
M, mutation.
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The presence of G12C mutation was confirmed in the
MiaPaCa-2 and Capan-1 carcinoma cell line, while it was not
observed in BxPC-3 line (Table 1) [16, 17].
first-line combined antibody therapy versus
gemcitabine
Gemcitabine dose was fixed at 150 mg/kg per injection and
antibody doses were selected on the basis of our previous
experiments [12].
In the three human pancreatic carcinoma xenografts, the
survival of mice treated with the 2mAbs was significantly
greater compared with gemcitabine (P = 0.0006 for BxPC-3, P =
0.0679 for MiaPaCa-2 and P = 0.0018 for Capan-1) and control
groups (P = 0.0001 for BxPC-3, P = 0.0006 for MiaPaCa-2
and P = 0.0025 for Capan-1) (Figure 1). Median delays for each
of the three tumors to reach a volume of 1000 mm3 under
2mAbs, gemcitabine or no treatment are reported in Table 2.
Only the groups treated with the 2mAbs showed complete
responses with 20%–33% of tumor-free mice after 2 months of
follow-up (Table 2).
second-line combined antibody therapy after
progression under gemcitabine
The two mAbs were injected to mice with larger tumors,
compared with first-line therapy, since a minimum two-fold
tumor progression had to be recorded at the time of 2mAbs
treatment initiation (Figure 2). In BxPC-3 and Capan-1 models
significant tumor regressions were observed when the mice
received 2mAbs, compared with continuous gemcitabine
injection group (P < 0.001), while in the MiaPaCa-2 model, 3
of 10 mice showed a marked tumor regression and the others
showed only a stabilization of tumor growth (P = 0.003).
Despite moderate tumor regrowth, observed after tumor
regressions or stabilization, survival was significantly longer in
mice from the three pancreatic carcinoma models, treated in
second line with 2mAbs compared with mice treated only with
gemcitabine (P = 0.008 for BxPC-3, P = 0.052 for MiaPaCa-2
and P = 0.0018 for Capan-1).
immunohistochemistry and western blot analysis
To assess the in vivo mechanisms underlying the antitumor
activity of the two mAbs combination, we analyzed in BxPC-3
tumor xenografts, by immunohistochemistry (IHC), the EGFR
expression, the EGFR phosphorylation level and the
proliferative Ki-67 index, after 1 week of 2mAbs or gemcitabine
treatment. As shown in Figure 3, the 2mAbs treatment induced
a marked decrease of the EGFR expression, EGFR
phosphorylation and Ki-67 index compared with untreated
controls and gemcitabine treatment. The AKT phosphorylation
after the same two treatments was assessed by western blot
analysis, which showed almost complete inhibition of P-AKT
after 2mAbs treatment and only minor inhibition after
gemcitabine treatment compared with untreated tumor control.
comparison of F(ab#)2 fragments from the 2mAbs
with intact antibodies
In order to separately analyze the in vivo direct effect of the
mAbs binding sites on the EGFR and HER2 receptor, as
compared with the Fc fragment-dependent effector functions of
the antibodies, F(ab#)2 fragments from both cetuximab and
trastuzumab were prepared and their therapeutic properties
evaluated. As shown in Figure 4, the F(ab#)2 fragments from the
two mAbs had a significant antitumor effect compared with
untreated controls (P < 0.001), as well as with F(ab#)2 from
anti-EGFR mAb alone, which had no antitumor effect (P =
0.510). As expected, injection of the two intact mAbs had
a more pronounced antitumor effect compared with the two
fragments (P = 0.002).
discussion
This preclinical study demonstrates a significant improvement
of survival and tumor regression in mice treated with combined
Figure 1. Kaplan–Meier survival curves of first-line combined anti-
epidermal growth factor receptor and anti-HER2 monoclonal antibodies
versus gemcitabine therapy. Percentage of mice with a tumor volume
<1000 mm3 as a function of time after graft under either combined anti-
epidermal growth factor receptor and anti-HER2 mAbs or gemcitabine or
no treatment controls. K-Ras WT, K-Ras wild type; K-Ras M, K-Ras
mutation.
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anti-EGFR (cetuximab) and anti-HER2 (trastuzumab) mAbs in
first and second line of treatment compared with gemcitabine,
the gold standard in pancreatic cancers [2].
Of particular interest was the positive impact of this
treatment despite the low HER2 expression by all three target
carcinomas and despite the presence of a K-Ras mutation on
two of them. It was recently shown that the efficacy of
cetuximab in metastastic colorectal carcinoma was almost
abolished in K-Ras-mutated tumors [18]. In pancreatic cancer,
where K-Ras mutations are the norm (90%), trials evaluating
cetuximab plus gemcitabine–cisplatin versus gemcitabine–
cisplatin did not increase response or survival of patients [19].
Here, a clear therapeutic benefit of cetuximab and trastuzumab
combination was observed in two K-Ras-mutated pancreatic
carcinomas, suggesting that the lack of clinical benefit of anti-
EGFR mAb could be bypassed by combining this mAb with the
anti-HER2 mAb.
All three tested pancreatic carcinoma lines responded better
to 2mAbs whatever their respective sensitivity to gemcitabine.
In case of high sensitivity to chemotherapy (BxPC-3), i.e. in the
best condition of gemcitabine efficacy, 2mAbs significantly
increased tumor responses and cured three of nine mice, while
no cure was obtained with gemcitabine.
The mechanism of action of the synergism of the two anti-
EGFR and HER2 mAbs is not yet entirely understood, as is the
case for several approved mAbs whose mode of action is not
entirely unraveled. It was shown that an anti-EGFR mAb could
increase the in vitro growth inhibition of an anti-HER2 mAb
[9] or that two anti-EGFR and HER2 mAbs had a synergistic
effect in the down-regulation of the receptor tyrosine kinases
activity [10]. However, our in vivo results were the first to
demonstrate unequivocally that the two anti-EGFR and HER2
mAbs can act synergistically in the treatment of human
carcinoma xenografts [12]. Thus, we concentrated our effort on
some in vivo experiments that could shed some light on the
mechanism of action of 2mAbs.
First, we showed that the 2mAbs induced a decrease of the
proliferation index Ki-67 and a down-regulation of the EGFR.
These results were in agreement with those from other groups
obtained after the injection of a single anti-EGFR or anti-HER2
mAbs [9–11] or by treatment with two mAbs directed against
different epitopes of either EGFR [20] or HER2 receptor [10].
Second, our more original in vivo results were obtained by the
combined injection of F(ab#)2 fragments from cetuximab and
trastuzumab in order to determine whether the tumor growth
inhibition observed with the two intact mAbs was due to a direct
action of the two antibody-binding sites on the two receptors,
by inhibiting their dimerizations or triggering of a negative
intracellular signal, as indicated by in vitro results [8–11] or if it
was due to an antibody-dependent cellular cytotoxicity
enhancement, as indicated by in vivo experiments [21]. Our
results show for the first time in vivo that F(ab#)2 from two anti-
EGFR and HER2 receptor mAbs significantly inhibited the
Table 2. Median survival and percent of cured mice after first-line
treatment
Xenograft Treatment Mediana
survival
Benefitb Tumor-free
mice %
(number)
BxPC-3 Control 55 0
Gemcitabine 88 +33 0
2mAbs 109 +54 33 (3/9)
MiaPaCa-2 Control 81 0
Gemcitabine 94 +13 0
2mAbs 122 +41 22 (2/9)
Capan-1 Control 44 0
Gemcitabine 48 +4 0
2mAbs 105 +61 20 (2/10)
aMedian: days after graft where 50% of the mice present a 1000 mm3 tumor
volume.
bBenefit: gain in days of the treatment versus control group.
2mAbs, anti-epidermal growth factor receptor and anti-HER2 monoclonal
antibodies
Figure 2. Tumor size evolution of second-line combined anti-epidermal
growth factor receptor and anti-HER2 monoclonal antibodies (2mAbs)
therapy after gemcitabine progression. Pancreatic carcinoma-bearing mice
were first treated with gemcitabine. At day 26, 37 or 40 for Capan-1,
MiaPaCa-2 and BxPC-3, respectively, half of the mice in each tumor group
were treated with the 2mAbs combination, while the other half received
continuous gemcitabine treatment.
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growth of a pancreatic carcinoma xenograft, indicating that they
can have a therapeutic efficiency independently from the Fc
fragment-mediated effector functions and thus due to their
direct binding activity to the HER1 and HER2 receptors. The
therapeutic activity of the two intact mAbs was superior to that
observed with the two F(ab#)2 fragments, suggesting that the
recruitment of effector cells also played a role in the therapeutic
efficiency of our 2mAbs treatment. Another explanation for the
more efficient therapeutic activity of the two intact mAbs is that
due to the property of their Fc fragment to react with FcRn
receptor [22], they have a much longer circulating half-life than
the F(ab#)2 [23].
Whatever the contribution of the two mentioned antitumor
mechanisms, the present results show that the combined use of
two anti-EGFR and anti-HER2 mAbs, broadly used in the
clinic, can be efficient in the treatment of human pancreatic
carcinoma xenografts with low expression of HER2 and in two
of them with K-Ras mutations. Most importantly, it
demonstrates that the combined anti-EGFR and HER2 therapy
is more efficient than the present standard chemotherapy,
gemcitabine. In this context, a phase I–II clinical trial evaluating
the combined cetuximab and trastuzumab in second-line
treatment of pancreatic carcinoma after gemcitabine first-line
progression appears justified and promising.
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Figure 3. Effect of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies (2mAbs) treatment, versus gemcitabine, on the epidermal
growth factor receptor (EGFR)expression, EGFR phosphorylation, proliferation index Ki-67 and AKT phosphorylation in BxPC-3 xenografts. Tumors were
resected 7 days after the beginning of therapy. Immunohistochemistry shows in (A) EGFR expression (magnification ·10); (B) EGFR phosphorylation
(magnification ·40); (C) Ki-67 index (magnification ·40). On the right respective histograms in % positive cells. Western blot analysis shows in (D) the
AKT phosphorylation. Glyceraldehyde-3-phosphate dehydrogenase served as leading control. Cetuximab + trastuzumab (C + T): 2mAbs.
Figure 4. Antitumor effect of the combined treatment with two F(ab#)2
fragments mAbs, compared with two intact mAbs. Mice bearing BxPC-3
pancreatic carcinoma were treated either by coinjection with F(ab#)2
fragments from both cetuximab and trastuzumab or with the intact anti-
epidermal growth factor receptor and anti-HER2 monoclonal antibodies
or by injection with F(ab#)2 fragments from cetuximab alone or were
untreated controls.
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